Corvus Pharmaceuticals
CRVS
92 hedge funds and large institutions have $167M invested in Corvus Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 10 reducing their positions, and 29 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 10
45% more capital invested
Capital invested by funds: $115M → $167M (+$51.7M)
14% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 29
8.03% more ownership
Funds ownership: 53.26% → 61.29% (+8%)
5% more funds holding
Funds holding: 88 → 92 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
30% less call options, than puts
Call options by funds: $702K | Put options by funds: $1.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.5M |
| 2 |
BlackRock
New York
|
+$11.6M |
| 3 |
PA
Perceptive Advisors
New York
|
+$5.23M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.86M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$12.9M |
| 2 |
Millennium Management
New York
|
-$5.96M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.21M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.47M |
| 5 |
Jane Street
New York
|
-$901K |
CRVS Hedge Fund Activity: Q2 2025 in Review
92 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2025, worth a combined $167M — up 45% from $115M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CRVS positions and 29 closed out — a net gain of 4 holders — while 32 added to existing stakes and 10 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $15.5M. The largest seller was Samlyn Capital, exiting entirely with an estimated $12.9M sold.
- 92 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2025, up from 88 in Q1 2025.
- Funds reported $167M of Corvus Pharmaceuticals stock for Q2 2025, up 45% quarter-over-quarter.
- 33 funds opened new Corvus Pharmaceuticals positions in Q2 2025 and 29 closed out, a net change of +4 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2025 was Point72 Asset Management, an estimated $15.5M added.
- The largest Corvus Pharmaceuticals seller in Q2 2025 was Samlyn Capital, an estimated $12.9M sold.
Based on aggregated 13F filings for Q2 2025.